Dielectric barrier discharge and jet type plasma surface modifications of hybrid polymeric poly (ε-caprolactone)/chitosan scaffolds
Source abstract
Abstract
In this study, dry air plasma jet and dielectric barrier discharge Ar + O 2 or Ar + N 2 plasma modifications and their effects on wettability, topography, functionality and biological efficiency of the hybrid polymeric poly (ε-caprolactone)/chitosan scaffolds were reported. The samples treated with Ar + O 2 dielectric barrier discharge plasma (80 sccm O 2 flow rate, 3-min treatment) or with dry air plasma jet (15-cm nozzle-sample distance, 13-min treatment) had the closest wettability (49.11 ± 1.83 and 53.60 ± 0.95, respectively) to the commercial tissue culture polystyrene used for cell cultivation. Scanning electron microscopy images and X-ray photoelectron spectrometry analysis showed increase in topographical roughness and OH/NH 2 functionality, respectively. Increased fluid uptake capacity for the scaffolds treated with Ar + O 2 dielectric barrier discharge plasma (73.60% ± 1.78) and dry air plasma jet (72.48% ± 0.75) were also noted. Finally, initial cell attachment as well as seven-day cell viability, growth and proliferation performances were found to be significantly better for both plasma treated scaffolds than for untreated scaffolds.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Surface Modification and Superhydrophobicity · Plasma Applications and Diagnostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Hacettepe University, Bioengineering Division, Ankara, Turkey
Department of Metallurgical and Materials Engineering, Atilim University, Ankara, Turkey
References (33)
Show source-provided references
1. 10.2174/2211542011302999000710.2174/22115420113029990007 ↗
2. 10.1016/j.ijbiomac.2011.07.02210.1016/j.ijbiomac.2011.07.022 ↗
3. 10.1016/j.jbiosc.2016.01.00410.1016/j.jbiosc.2016.01.004 ↗
4. 10.1016/j.ijbiomac.2016.07.01310.1016/j.ijbiomac.2016.07.013 ↗
5. 10.1016/j.jcis.2016.03.02010.1016/j.jcis.2016.03.020 ↗
6. 10.1016/j.colsurfb.2016.02.05010.1016/j.colsurfb.2016.02.050 ↗
7. 10.1016/j.actbio.2015.01.03010.1016/j.actbio.2015.01.030 ↗
8. 10.1016/j.ijbiomac.2012.11.01310.1016/j.ijbiomac.2012.11.013 ↗
9. 10.1016/j.ijpharm.2011.02.00410.1016/j.ijpharm.2011.02.004 ↗
10. 10.1080/09205063.2015.111171710.1080/09205063.2015.1111717 ↗
11. 10.1016/j.actbio.2016.06.01110.1016/j.actbio.2016.06.011 ↗
12. 10.1016/j.ijpharm.2015.11.05510.1016/j.ijpharm.2015.11.055 ↗
13. 10.1016/j.actbio.2016.04.00810.1016/j.actbio.2016.04.008 ↗
14. 10.1016/j.cej.2015.12.07910.1016/j.cej.2015.12.079 ↗
15. 10.1016/j.cej.2015.12.04710.1016/j.cej.2015.12.047 ↗
16. 10.1016/S0142-9612(02)00128-X10.1016/S0142-9612(02)00128-X ↗
17. 10.1163/156856209X44447510.1163/156856209X444475 ↗
18. 10.1016/j.apsusc.2016.05.12310.1016/j.apsusc.2016.05.123 ↗
19. 10.2478/v10136-009-0013-910.2478/v10136-009-0013-9 ↗
20. 10.1016/j.tsf.2013.02.03810.1016/j.tsf.2013.02.038 ↗
21. 10.1016/j.apsusc.2008.03.04910.1016/j.apsusc.2008.03.049 ↗
22. 10.1016/j.msec.2010.12.01210.1016/j.msec.2010.12.012 ↗
23. 10.1016/j.actbio.2016.09.03010.1016/j.actbio.2016.09.030 ↗
24. 10.1080/00914037.2016.127821810.1080/00914037.2016.1278218 ↗
25. 10.1109/TPS.2008.91716710.1109/TPS.2008.917167 ↗
26. 10.1063/1.291790810.1063/1.2917908 ↗
27. 10.1007/s11090-012-9419-310.1007/s11090-012-9419-3 ↗
28. 10.1023/A:102247090138510.1023/A:1022470901385 ↗
29. 10.1002/ppap.20060002110.1002/ppap.200600021 ↗
30. 10.1016/j.jcis.2012.02.05610.1016/j.jcis.2012.02.056 ↗
31. 10.1016/S0142-9612(03)00247-310.1016/S0142-9612(03)00247-3 ↗
32. 10.1016/j.msec.2014.12.01010.1016/j.msec.2014.12.010 ↗
33. 10.1016/j.msec.2014.06.03710.1016/j.msec.2014.06.037 ↗